Fluconazole

Product Used For Unknown Indication	29.3%
Candidiasis	9.0%
Fungal Infection	6.2%
Hiv Infection	6.0%
Ill-defined Disorder	5.2%
Drug Use For Unknown Indication	4.6%
Oral Candidiasis	4.4%
Immunosuppression	4.3%
Vulvovaginal Candidiasis	4.3%
Antifungal Prophylaxis	4.0%
Antibiotic Prophylaxis	3.2%
Prophylaxis	3.2%
Acute Promyelocytic Leukaemia	2.6%
Meningitis Cryptococcal	2.3%
Tuberculosis	2.2%
Renal Transplant	2.0%
Hypertension	1.9%
B-cell Lymphoma	1.8%
Infection	1.8%
Candida Infection	1.8%

Drug Interaction	9.2%
Vomiting	8.0%
Rhabdomyolysis	7.6%
Drug Ineffective	7.4%
Torsade De Pointes	6.8%
Urticaria	5.8%
Renal Impairment	5.4%
Toxic Epidermal Necrolysis	4.8%
Stevens-johnson Syndrome	4.6%
Pancytopenia	4.4%
Drug Eruption	4.2%
Drug Resistance	3.8%
Rash	3.8%
Thrombocytopenia	3.8%
International Normalised Ratio Increased	3.6%
Alopecia	3.4%
Multiple-drug Resistance	3.4%
Septic Shock	3.4%
Renal Failure Acute	3.2%
Vulvovaginal Pruritus	3.2%

Secondary

Product Used For Unknown Indication	30.3%
Drug Use For Unknown Indication	15.8%
Hiv Infection	9.9%
Prophylaxis	6.0%
Drug Abuse	4.1%
Antifungal Prophylaxis	3.6%
Candidiasis	3.2%
Hypertension	2.8%
Antibiotic Prophylaxis	2.7%
Fungal Infection	2.5%
Chemotherapy	2.5%
Infection	2.3%
Pneumonia	2.1%
Pain	2.0%
Tuberculosis	2.0%
Oral Candidiasis	1.7%
Immunosuppression	1.6%
Candida Infection	1.6%
Immunosuppressant Drug Therapy	1.6%
Sepsis	1.6%

Vomiting	9.1%
Toxic Epidermal Necrolysis	8.7%
Renal Failure Acute	6.5%
Thrombocytopenia	6.5%
Drug Rash With Eosinophilia And Systemic Symptoms	5.7%
Weight Decreased	5.6%
Rhabdomyolysis	5.2%
Stevens-johnson Syndrome	5.2%
Pyrexia	5.0%
Drug Ineffective	4.8%
Loss Of Consciousness	4.8%
Drug Interaction	4.3%
Toxic Skin Eruption	3.9%
Metabolic Acidosis	3.7%
Sepsis	3.7%
Septic Shock	3.7%
Renal Failure	3.5%
Systemic Candida	3.5%
Tuberculosis	3.5%
White Blood Cell Count Decreased	3.1%

Concomitant

Product Used For Unknown Indication	27.3%
Drug Use For Unknown Indication	18.1%
Prophylaxis	9.0%
Hiv Infection	7.6%
Infection Prophylaxis	4.1%
Multiple Myeloma	4.0%
Pain	3.5%
Antifungal Prophylaxis	3.2%
Acute Lymphocytic Leukaemia	2.6%
Hypertension	2.5%
Acute Myeloid Leukaemia	2.5%
Diffuse Large B-cell Lymphoma	2.3%
Prophylaxis Against Graft Versus Host Disease	2.3%
Nausea	1.7%
Premedication	1.7%
Bone Marrow Conditioning Regimen	1.6%
Aplastic Anaemia	1.6%
Constipation	1.5%
Depression	1.5%
Infection	1.4%

Vomiting	11.7%
White Blood Cell Count Decreased	8.8%
Thrombocytopenia	8.1%
Sepsis	7.7%
Pyrexia	7.5%
Weight Decreased	6.2%
Pulmonary Embolism	5.5%
Pneumonia	5.1%
Febrile Neutropenia	5.0%
Renal Failure Acute	4.2%
Death	4.1%
Septic Shock	3.4%
Respiratory Failure	3.3%
Renal Failure	3.2%
Urinary Tract Infection	2.9%
Weight Increased	2.8%
Pain	2.7%
Neutropenia	2.7%
Nausea	2.6%
Rash	2.3%

Interacting

Product Used For Unknown Indication	51.0%
Renal Transplant	7.5%
Immunosuppression	4.5%
Fungal Peritonitis	3.9%
Mycobacterium Avium Complex Infection	3.1%
Acquired Immunodeficiency Syndrome	2.8%
Cytomegalovirus Chorioretinitis	2.8%
Oropharyngeal Candidiasis	2.8%
Candidiasis	2.7%
Endocarditis Bacterial	2.6%
Oral Candidiasis	2.2%
Analgesic Therapy	2.0%
Depression	2.0%
Drug Use For Unknown Indication	1.8%
Atrial Fibrillation	1.6%
Hypertension	1.5%
Delirium	1.4%
Ewing's Sarcoma	1.4%
Hiv Infection	1.4%
Antifungal Prophylaxis	0.9%

Drug Interaction	29.9%
Thrombocytopenia	9.7%
Drug Level Increased	7.8%
Immunosuppressant Drug Level Increased	6.5%
Iron Deficiency Anaemia	6.5%
Renal Failure Acute	5.2%
Toxicity To Various Agents	4.5%
Complications Of Transplanted Kidney	3.2%
Depressed Level Of Consciousness	3.2%
International Normalised Ratio Increased	3.2%
Vertigo	3.2%
Rhabdomyolysis	2.6%
Strabismus	2.6%
Graft Versus Host Disease	1.9%
Neutropenia	1.9%
Serotonin Syndrome	1.9%
Shock Haemorrhagic	1.9%
Agitation	1.3%
Bilirubin Conjugated Increased	1.3%
Blood Creatinine Increased	1.3%